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Abstract 
Little is known about the effect of community versus health facility-based 
interventions to improve and sustain antiretroviral therapy (ART) adherence, 
virologic suppression, and retention in care among HIV-infected individuals in low- 
and middle-income countries (LMICs). We systematically searched four electronic 
databases for all available randomized controlled trials (RCTs) and comparative 
cohort studies in LMICs comparing community versus health facility-based 
interventions. Relative risks (RRs) for pre-defined adherence, treatment engagement 
(linkage and retention in care), and relevant clinical outcomes were pooled using 
random effect models. Eleven cohort studies and eleven RCTs (N = 97,657) were 
included. Meta-analysis of the included RCTs comparing community- versus health 
facility-based interventions found comparable outcomes in terms of ART adherence 
(RR = 1.02, 95 % CI 0.99 to 1.04), virologic suppression (RR = 1.00, 95 % CI 0.98 to 
1.03), and all-cause mortality (RR = 0.93, 95 % CI 0.73 to 1.18). The result of pooled 
analysis from the RCTs (RR = 1.03, 95 % CI 1.01 to 1.06) and cohort studies (RR  
= 1.09, 95 % CI 1.03 to 1.15) found that participants assigned to community-based 
interventions had statistically significantly higher rates of treatment engagement. 
Two studies found community-based ART delivery model either cost-saving or cost-
effective. Community- versus facility-based models of ART delivery resulted in at 
least comparable outcomes for clinically stable HIV-infected patients on treatment in 
LMICs and are likely to be cost-effective. 
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Introduction 
The number of people that have started  life-saving antiretroviral therapy (ART) has 
importantly increased in low- and middle-income countries [1]. However, this positive 
development has led to health facilities’ overcrowding, longer waiting times during visits, and 
reduced time for counseling and clinical care of newly enrolled patients.  In most public sector 
clinics in resource-limited settings, it has also restricted the workforce’s capacity to provide 
ongoing adherence support and track patients lost to follow-up to ensure optimal ART effects 
on patient health and community HIV prevention. [2]. Further, in July 2014, UNAIDS called 
for a global scale-up of Treatment as Prevention (TASP) and efforts to meet the following ‘90-
90-90’ targets by 2020: (1) 90% of all people living with HIV should know their HIV status 
(90% diagnosed); (2) 90% of all people diagnosed with HIV infection  should receive ART 
(90% on treatment); and (3) 90% of all people receiving ART should achieve viral suppression 
(UNAIDS 2014)[3]. This ambitious target is supported by the latest World Health 
Organization (WHO) guidelines recommending treating all HIV positive individuals 
irrespective of immune status. It implies that an additional 21 million people are now eligible 
for treatment [4]. This underscores the importance of expanding health systems’ capacity to 
meet communities’ growing health needs.   
 
 
Emerging data from both developed and developing countries demonstrate that a substantial 
reduction in patient retention in medical care occurs between each stage of the HIV treatment 
continuum, or cascade—from diagnosis and linkage to care, assessment of ART readiness to 
acceptability, receipt of initial ART, adherence and long-term retention in care, and treatment 
success as reflected by virologic suppression [5-8]. A systematic review by Fox and Rosen 
reported that retention of HIV-infected adults on ART at 36 months in middle- and low-
income countries averages only 65% to 70%[9]. Success along the HIV treatment cascade is 
even worse in vulnerable populations, namely, pregnant women, children and adolescents, sex 
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workers, injecting drug users, and men who have sex with men; and they are at high risk of 
acquiring as well as transmitting the HIV virus, thus experiencing poor clinical and public 
health outcomes [10-15]. Against this background, it is critical to determine how effective 
interventions are at every level of the treatment cascade to prevent new infections and promote 
health outcomes to achieve the goal of an AIDS- free generation [7].  
 
In Africa, selected approaches to reducing loss at every stage of the HIV treatment cascade 
include decentralization of services and task-shifting aspects of care to nurses and to non-
clinical staff, including lay counselors who may be patients themselves. These approaches have 
been found to be feasible and to result in good clinical outcomes and are now recommended 
and being scaled up in resource-limited settings [16-19]. However, such facility-based 
approaches are reaching their limits as increasing numbers of patients initiate ART. Recently, 
suggestions have been made to expand accessible and flexible community-based ART services 
delivery, differentiating the needs of clinically ill patients starting ART or in need of significant 
adherence counseling from the needs of clinically stable ongoing patients with documented 
good adherence.  Such , have been suggested as important strategies for maintaining and 
improving ART adherence, retention and quality of care [16]. 
 
Indeed, community and home-based programs  to promote ART adherence and/or retention 
in HIV care are now increasingly being recognized as an important and sustainable approach 
that could contribute significantly toward the UNAIDS 90-90-90 target and ultimately an 
AIDS-Free generation [20-32]. In addition, they are also seen as an essential mechanism of 
service delivery, including dispensing of ART, and a means of decongesting formal health 
services, rather than being purely an adherence adjunct. Furthermore, such interventions are 
likely to be cost-effective by offering a shift of certain tasks from overburdened healthcare 
settings directly into communities [33,34].  
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We aimed to conduct a systematic review and meta-analysis to compare the effect of 
community-based ART delivery on adherence, virologic outcomes, retention in care and all-
cause mortality among HIV-infected individuals in middle- and low-income countries against 
results obtained through standard health facility care.     
 
Methods 
Protocol 
The study background, rationale, and methods were specified in advance and documented in 
a study protocol registered in the PROSPERO database (CRD42016034114). 
 
Study Inclusion Criteria 
In order to be eligible for inclusion in the review, studies had to report on adherence, and/or 
virologic suppression, and/or lost-to-follow up outcomes after initiation of ART. The following 
selection criteria were used to identify potential studies: 
 Study design:  Observational and experimental studies with primary data using cross-
sectional, case – control, and cohort (prospective and retrospective) and randomized 
controlled trials (RCT s) designs 
 Study population: HIV-infected individuals initiated on ART. 
 Intervention: Community-based ART delivery. Models could include: 1) home-based 
interventions (e.g. friends or family-centred approaches); 2) peer- or HIV patients-led 
interventions; community ART distribution points (with or without involving primary 
level formal or informal health facilities); 3) community-based ART adherence clubs (with 
or without involving primary level formal or informal health facilities); 4) community ART 
groups (CAGs) 
 Comparator:  health-facility (e.g. hospital or clinics) 
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 Outcomes:  Primary: 1) Proportion of HIV-infected patients with optimal ART adherence 
levels* (>80%); 2) Proportion of HIV-infected patients with virologic suppression (as 
defined by the studies) at 12 and 24 months’ post ART initiation. Secondary: Proportion of 
patients lost-to-follow up as defined by the studies at 12 and 24 months’ post Art initiation; 
all-cause mortality; and cost to patient and provider. 
Data Sources and Searches 
We conducted a systematic literature search using the following databases: Medline 
(PubMed), Scopus, SCI Web of Science and Cochrane Central Register of Controlled Trials 
(CENTRAL) through January 2016. In addition, abstracts from major HIV/AIDS or infectious 
diseases conferences such as the Conference on Retrovirus and Opportunistic Infections 
(CROI), International AIDS Society (IAS), International AIDS Conference and Infectious 
Diseases Society of America (IDSA) were reviewed for inclusion. 
Our search terms included: “community”; ‘home-based care”; “health facilities”; "adherence"; 
“adherence club”; “retention in care”; “retention”; “loss to follow up”, “attrition”, 
"antiretroviral therapy"; “HIV”;  “community volunteers”; “treatment supporter”; “DAART”; 
“cost”. 
 
Study Selection and Data Extraction 
Two of the authors (JBN and OA) screened the search outputs using titles and abstracts and 
independently went through the full text of all potentially eligible studies to assess whether 
they meet the inclusion criteria. Discrepancies in the choice of included studies between the 
two authors were resolved through discussion and consensus. For all eligible studies, the same 
authors reviewed extracted information regarding publication date, study setting, study 
design, methods, patient population, study intervention, and outcomes. 
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Risk of bias (quality) assessment 
To appraise the risk of bias for included studies, a tool was adapted from the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) (Appendix) [35]. Briefly, 
the risk of bias was assessed as low risk, unclear risk or high-risk for each of the following 
domains: selection (sample population), selection (participation rate), performance bias 
(outcome assessment), performance bias (analytical methods to control for bias) and other 
forms of bias. We used the Cochrane Collaboration’s tool for assessing the risk of bias for 
quality assessment of the included studies[36]. The studies were graded based on: (i) sequence 
generation, (ii) blinding of outcome assessor, (iii) incomplete outcome data, (iv) selective 
outcome reporting, and (v) other sources of bias.  
 
 
Measures of treatment effect and unit of analysis 
We used relative risks (RR) for the calculation of dichotomous data (such as adherence and 
retention in care) and mean differences for continuous data (such as change in CD4 cell count. 
All the results are presented with 95 % confidence intervals (CI).    
Data Synthesis  
In the absence of statistical heterogeneity, we used a fixed-effect model, and we used a 
random-effects model where we detected moderate heterogeneity and it was deemed still 
reasonable to combine trials.   We assessed the presence of statistical heterogeneity in the 
meta-analyses by visual inspection of the forest plot and applying a chi-squared test for 
heterogeneity with a threshold P value of 0.10 to determine statistical significance. 
Inconsistency was quantified across studies using the I2 value. We used Review Manager 5.3 
[37] to conduct analyses and analyzed results for trials and cohort studies separately and also 
pooled these data. This review was reported according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement [38]. 
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Results 
Study selection and characteristics of included studies 
The process of study identification and selection is shown in Figure 1. The literature search 
yielded 7,928 citations after removing duplicates. After review of the title and abstract, 33 full 
text articles were selected for critical review. A total of eleven trials were included 
[21,25,26,29,30,36,39-44] and eleven cohort studies [27,36,39,45-54]with a total of 5861 and 
89,388 participants, respectively. These studies were conducted in eight different sub-
Saharan African countries, including Botswana, Zimbabwe, South Africa, Nigeria, Uganda, 
Kenya, Tanzania and Zambia. Other studies were conducted in other low and middle income 
countries such as Brazil, Haiti, Peru and Thailand. See additional details in Table 1. We 
excluded seventeen studies. One study was excluded due to inclusion of a non-African 
population[44], four studies were excluded due to non-inclusion of community based data 
[32,55-57] while seven studies were excluded because the studies were non comparative in 
nature [19,58-62]. A study was also excluded because only baseline data were reported[63] 
while four did not show data for different arms of the studies[17,64-66].  
 
Risk of bias in included studies 
The risk of bias of included cohort studies is summarised in Table 2.  All the included studies 
had low risk of bias with respect to the selection of sample population and explaining the 
rationale for case and control selection while the included cohort studies were at risk of bias 
for sample selection ambiguity and having samples that were unlikely to be representative. All 
the studies had a high participation rate (>70-85%). In terms of outcome assessment, seven 
of the included studies had objective measures of adherence such as ‘pill count’, while two had 
high risk of bias by measuring the outcome using self-reporting format. All the trials and 
cohort studies used one or more analytical methods to control for bias in individual studies. 
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The risk of bias in the included studies was highest from other form of bias, followed by 
selection of sample population, and lowest from participation rates and analytical methods to 
control for bias.   
 
The risk of bias of included trials is shown in Table 3. Allocation sequence generation was 
adequate in all the eleven trials. Allocation concealment was adequate in nine trials and 
unclear in the remaining two trials. Masking of outcome assessors was not clear in all the nine 
trials. Potential risk of bias due selective reporting and other bias was low in all eleven trials. 
 
Optimal ART adherence 
Seven RCTs and three cohort studies reported optimal adherence as an outcome. Individual 
and pooled RRs for optimal adherence are shown in Figure 2. The result of pooled analysis 
from the RCTs showed no statistically significance difference in optimal adherence rates 
between the two treatment groups (pooled RR = 1.02, 95% CI 0.99 to 1.04, I2 = 68%), such 
that among 6358 participants randomised to community-based ART 5827 (91.7%) achieved 
optimal ART adherence compared with 4083 of 4619 in the facility-based ART group (88.4%). 
However, three cohort studies provided evidence that participants in community-based ART 
had statistically significant higher optimal adherence rate compared to those in facility-based 
ART group (RR = 1.80, 95% CI 1.04 to 3.13), such that among 274 participants randomised to 
community-based ART 295 (92.9%) achieved optimal ART adherence compared with 196 of 
288 in the facility-based ART group (68.1%). 
 
Virologic suppression 
Eight RCTs and Eight cohort studies reported virologic suppression as an outcome. Individual 
and pooled RRs for virologic suppression are shown in Figure 3. The result of pooled analysis 
from the RCTs showed no statistically significance difference in virologic suppression rates 
between the two treatment groups (pooled RR = 1.00, 95% CI 0.97 to 1.03), with evidence of 
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no statistically significant heterogeneity between studies (I2 = 0%, p=0.49). Similarly, the 
result of pooled analysis from the cohort studies showed no statistically significant difference 
in virologic suppression rates between the two treatment groups (pooled RR = 1.06, 95% CI 
0.77 to 1.46), with evidence of statistically significance substantial heterogeneity between 
studies (I2 = 100%, p<0.00001). 
 
 
Retention in care 
Seven RCTs and four cohort studies reported retention in care as an outcome. Individual and 
pooled RRs for retention in care are shown in Figure 4. The result of pooled analysis from 
the RCTs showed that participants assigned to community-based ART (80.3% [3157 of 3931]) 
had statistically significant higher rates of retention in care than those in facility-based ART 
(75.9% [2334 of 3074]) at the end of the follow-up period (RR = 1.03, 95% CI 1.01 to 1.06, I2 = 
0%). Similarly, the result of pooled analysis from the cohort studies showed that participants 
assigned to community-based ART (89.4% [1074 of 1203]) had statistically significant higher 
rates of retention in care than those in facility-based ART (84.9% [2578 of 3038]) at the end 
of the follow-up period (RR = 1.09, 95% CI 1.03 to 1.15, I2 = 69%) 
 
 Change in CD4+ T-cell count 
Three RCTs reported CD4+ T-cell count as an outcome. The results of pooled analysis from 
the three RCTs show no significance difference in change in CD4+ T-cell count between the 
two treatment groups (mean difference = 0.93, 95% CI -11.36 to 13.21, I2 = 0%) (Figure 5).  
 
All-cause mortality 
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Ten RCTs and eight cohort studies reported all-cause mortality as an outcome. Individual and 
pooled RRs for all-cause mortality are shown in Figure 6. The result of pooled analysis from 
the RCTs showed there was no statistically significant difference in rates of all-cause mortality 
in assigned to community-based ART (9.3% [388 of 4160]) than those assigned to facility-
based ART (10.3% [338 of 3272]) at the end of the follow-up period (RR = 0.93, 95% CI 0.73 
to 1.18, I2 = 38%). Similarly, the result of pooled analysis from the cohort studies showed there 
was no statistically significant difference in rates of all-cause mortality in assigned to 
community-based ART (4.2% [1,075 of 25,506]) than those assigned to facility-based ART 
(6.0% [3,299 of 54,708]) at the end of the follow-up period (RR = 0.44, 95% CI 0.19 to 1.02, 
I2 = 96%). 
 
Loss to follow-up 
Six RCTs and seven cohort studies reported loss to follow-up as an outcome. Individual and 
pooled RRs for loss to follow-up are shown in Figure 7. The result of pooled analysis from the 
RCTs showed there was no statistically significant difference in rates of loss to follow-up in 
assigned to community-based and those assigned to facility-based ART at the end of the 
follow-up period (RR = 0.88, 95% CI 0.77 to 1.11, I2 = 0%). However, the result of pooled 
analysis from the cohort studies showed that the rate of loss to follow-up was statistically 
significantly lower in those participants in community-based ART (5.1% [1,289 of 25065]) 
than those in facility-based ART (9.7% [5268 of 54,545]) at the end of the follow-up period 
(RR = 0.34, 95% CI 0.14 to 0.81, I2 = 97%). 
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Cost to the patient and provider 
Jaffar et al.[25] reported costs to access care per patient including transport, lunch, child care 
costs and lost work time. The average total cost per patient in the first year was US $29 among 
the community-based participants compared to the US $60 facility-based patients. In terms 
of health-service costs, the same study reported average cost per patient per year to be US$793 
among the community-based participants compared to US$838 among facility-based patients 
in Jinja, Uganda. Also, Bango and colleagues reported from South Africa, that ART adherence 
clubs (AAC) were most cost-effective than standard of care (SOC), with a cost per patient year 
of $296  for AAC vs. $374 for SOC. Retention in care at one year was 95% (95% CI: 94.88-
95.86) for SOC, and 98% for ACC (95% CI: 97.6-98.3)[67]. 
 
 
Discussion 
This meta-analysis of nine cohort studies and seven RCTs found no statistical difference in 
optimal ART adherence, virologic suppression, change in CD4+ T-cell count, all-cause 
mortality and loss to follow-up between those participants assigned to community-based ART 
and facility-based ART, when analysis was restricted to RCTs.  However, in the pooled analysis 
from both RCTs and cohort studies, we documented that participants assigned to community-
based ART had significantly higher rates of retention in care than those in facility-based ART 
at the end of the follow-up period. 
 
The above results corroborate the fact that providing patient support and education programs 
at community level are not inferior compared to facility-based ones and may in fact be superior 
when it comes to selected outcomes such as lost-to-follow up. Of note, our analysis may be 
underpowered to show superiority on selected outcomes such as virological outcomes and all-
cause mortality. Furthermore, it appears that mortality in the observational studies might be 
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slightly higher in the community-based studies whereas retention and loss to follow-up seems 
to suggest that these outcomes in community-based are better than facility-based.  It is 
possible that they are both likely artefacts, particularly in the non-randomized studies, of the 
fact that outcome ascertainment is better in the community than in the facility based studies 
since mortality in facility-based studies may be under-ascertained, this will make mortality in 
the community look higher[68].  At the same time, silent and even official community patient 
transfers in facility based also tend to be under-captured, thus making retention look 
worse[68].   For these reasons, studies, retention outcome is usually retention in facility and 
therefore interpretation of such outcome must with caution. 
 
 
 
In building decentralized ART delivery, adherence and retention in care support, community-
based ART programs encourage patient autonomy, build social networks and minimize the 
structural barriers, such as cost of transport to the clinic, which in turn appear to result in 
better outcomes.  Such community-based interventions are likely to be impactful since they 
tend to involve trained community health workers, peers, volunteers, or patient’s own social 
network members (e.g., family and friends) who assist with ART adherence counselling and 
support.  In addition, there is evidence that they may provide material, instrumental and 
emotional support, as well as promote other healthy behaviours, such as decreased alcohol 
and drug use, leading to better health outcomes--- including survival [14,24,29,32]. 
Furthermore, enhancing certain aspects of the patient–supporter relationships—such as trust, 
supporter availability, communication, reciprocity of support, and medication assistance—in 
a manner consistent with patients' expectations may help to optimize the relationship, and its 
positive impact on patient health [14,24,29]. 
 
Our study complements the findings of a previous review that assessed the effect of home-
based interventions on viral outcomes in sub-Saharan Africa; this review found that there was 
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insufficient data to be conclusive [69]. Another recent review summarized the evidence 
supporting different models of community participation for ART care, or community-based 
ART in sub-Saharan Africa; these  community ART programs made treatment readily 
accessible and affordable[70]. In Uganda and Kenya community health workers or volunteers 
delivered ART at home [41,62] while in Tete, Mozambique a demonstration project of people 
living with HIV/AIDS used self-formed community-based ART groups to deliver ART in the 
community [19].  Also, in South Africa, Medicines Sans Frontiers, piloted ART adherence clubs 
with promising results[27]. These clubs may provide some adherence counseling and peer 
support, as well as enable a “fast track” refill mechanisms. Patients are placed in groups of 
approximately six patients and one member of the group (rotating each month) is permitted 
to obtain refills for all of the patients in his or her group. These approaches decrease the patient 
burden on health facilities, reduce transportation costs and waiting times for patients, and 
help overcome structural barriers. They also reduce treatment fatigue and loss to follow up, 
increase disclosure and treatment education, and may help patients develop necessary social 
ties.   While supportive of community-based interventions, these evaluations used 
observational study designs with possibility of selection and observational bias as well as 
confounding and most of them did not have a valid comparator and could not be included in 
our meta-analysis.  
 
We also investigated as secondary outcomes two potential concerns related to community-
based ART adherence and retention programs, including reported stigma and low quality of 
care which could result in an increased all-cause mortality. In terms of stigma, an RCT 
reported that only 3% of patients refused to participate in the home-based ART program due 
to stigma [25] Furthermore, it has even been suggested that involvement of community-health 
care workers in HIV care reduced stigma[71] and  being part of peer groups has been found to 
decrease the perception of social stigma [72].  
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Our results have important clinical and public health implications in the context of reaching 
UNAIDS 90-90-90 target for an AIDS-free generation: first, community-based interventions 
aim to deliver a package of essential ART care functions beyond the clinic  into the community 
such as ART refills, monitoring of treatment adherence and outcomes, and detection of sick 
patients and rapid referral to care. This, in turn, frees up capacity within the clinic-based 
medical workforce to be able to focus on complicated tasks such as clinical care for sick 
patients, training and supervision of lower cadres, and management of health care services. 
Second, community-based ART delivery and adherence monitoring and support models for 
clinically stable patients with documented virological suppression holds the potential of 
enabling countries to build sustainable, cost effective and equitable HIV care for populations 
in countries with a scarce health care workforce. Indeed, a cost-effectiveness study by 
Marseille and colleagues concluded that a home-based ART programme in rural Africa may 
be more cost effective than most previous estimates for facility-based HAART programs [73]. 
Only three cohort studies, Fatti et al. [46], Grimwood et al. [49] and Massavon et al. [52] 
involved children. The outcomes reported by these studies were virological suppression, 
mortality and loss to follow up and all of these were not different from what was obtainable in 
the adult population. These studies were conducted in South Africa and Uganda 
Our study has several strengths. We performed a comprehensive search of several databases 
and sources to identify eligible cohorts and RCTs with the latter providing the highest quality 
of evidence. Two authors independently evaluated each study for inclusion and data 
extraction. Regarding limitations, inclusion of cohort study designs may bias the overall 
estimate of effects due to unmeasured confounding not adjusted for in multivariate analyses. 
Indeed, the fact that we are observing a difference between RCTs and observational studies for 
the ART adherence outcome may reflect that in many if not all of these community based 
interventions, the patients who end up in the intervention, if it is not randomized, are likely to 
be quite a bit different – selected somehow – for stability even if not measured. However, in 
the context of implementation science, observational studies often provide strong signals of 
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important direction of effect. We could not do subgroup analysis for the primary outcomes 
based on the location of studies ie sub-Saharan African population versus other low and 
middle income countries. Finally, with only eleven RCTs, we may be underpowered to show 
superiority of either type interventions. 
 
 
In summary, we found that community as compared to facility-based ART interventions were 
effective in achieving optimal ART adherence and virologic suppression. Retention in HIV care 
was not different in the two groups, but, overall, we found lower all-cause mortality and loss 
to follow up in favour of community-based interventions, mostly within cohort studies rather 
than RCTs. As ART rollout expands in Africa and the need of health systems to adjust for such 
expansion in Africa, community-based ART delivery adherence monitoring and support 
models for stable patients hold the promise of enabling countries to build sustainable, cost 
effective and equitable HIV care for populations in countries with a scarce health workforce. 
Further research with well powered studies may be needed to further explore effectiveness of 
such community-based ART programs and their cost-effectiveness and the resources needs of 
families and communities to sustain optimal outcomes. 
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Tables  
Table 1   Table of included studies 
Study Type  
 
Age –median (years) 
 
Countries 
included 
Duration of 
study 
Sample 
size (n) 
 Participants  / healthcare service  
description  
Intervention Comparator  Intervention Comparator 
Chang et al. 
[21] 
Cluster-
randomized 
trial 
35.5       34.0        South 
Africa 
27 months; 
May 2006 - 
July 2008 
1,336  Patients with 
Community-based 
peer health workers 
Control group- 
accessing 
standard of care 
 
Fatti et al. 
[45] 
Cohort 35.1                34.6 South 
Africa 
69 months ; 
January 2004 - 
September  
2010 
66,953  Patients who received 
community-based 
adherence support 
Patients 
without 
community-
based 
adherence 
support 
 
Fatti et al. 
[46] 
Cohort 6.3 6.6 South 
Africa 
69 months; 
January 2004 - 
September  
2010 
4,853  Patients who received 
community-based 
adherence support 
Patients 
without 
community-
based 
adherence 
support 
 
Franke et 
al. [47] 
Prospective 
cohort 
37.0 37.0 Rwanda 15 months; 
June 2007 to 
August 2008 
 
610  Community-Based 
Accompaniment 
Clinic-Based 
Care 
Grimsrud et 
al. [48] 
Cohort 33.9 33.2 South 
Africa 
20 months; 
May 2012 - 
December 2013 
 
8,150  Community based 
adherence club  
Community 
Health Centre  
Grimwood 
et al. [49] 
Cohort 6.8 6.2 South 
Africa 
57 months; 
January 2004 - 
September 
2009 
 
3563  Children with patient 
advocates 
Children 
without patient 
advocates 
Jaffar et al. 
[25] 
Cluster-
randomized 
equivalence 
trial 
 
37.0 38.0 Uganda 48 months; 
February 2005 
- January 2009 
1,453  Home-based care  
 
Facility based 
care 
Johnston et 
al [50] 
Retrospective 
cohort 
36.0 43.0 South 
Africa 
75 months; 
January 2003 - 
March 2010 
417  Community cohort Workplace 
cohort 
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Kipp et al. 
[51] 
Cohort 36.8 34.8 Uganda 15 months; 
March 2006 - 
May 2007 
 
385  Centre/Community-
based cohort 
Hospital-based 
cohort 
Kiweewa et 
al. [39] 
Randomized 
controlled trial 
27.0 27.8 Uganda 29 months; 
May 2007 - 
September 
2009 
 
92  Nurse–Peer model 
 
Doctor–
Counsellor 
model 
Luque-
Fernandez 
et al. [27] 
Cohort Not reporter Not reported South 
Africa 
40 months; 
November 
2007 - 
February 2011 
 
2,834  Adherence clubs Traditional 
clinic-based 
care 
Massavon 
et al. [52] 
Retrospective 
cohort 
91.0 months 45.9 months Uganda 2003-2010 1,623  Community home-
based care approach 
 
Facility-based 
family-centred 
approach 
Mfinanga et 
al. [40] 
Open-label, 
randomized 
controlled trial 
 
38.0 
35.0 
37.0 
35.0 
Tanzania 
Zambia 
19 months; 
February, 2012 
- September, 
2013 
1,999   Clinic plus community 
support 
Standard care 
Nachega et 
al. [29] 
Open-label, 
randomized 
controlled trial 
 
35.7  36.7  South 
Africa 
42 months; 
February 2005 
– July 2008 
274  Directly observed 
therapy (DOT-ART) 
arm 
Self-
administered 
ART (Self-ART 
arm) 
 
Selke et al. 
[41] 
Cluster 
randomized 
controlled 
clinical trial 
 
38.7  37.5  Kenya 26 months; 
March 2006 - 
April 2008. 
208  Community Care 
Coordinators arm 
patients 
Standard of 
Care arm 
patients 
Taiwo et al 
[42] 
 
 
Randomized 
controlled trial 
 
 
Not reported 
 
 
 
Not reported 
 
 
 
Nigeria 
 
 
 
19 months; 
June 2006 - 
December 2007 
 
499 
 
 
 
 Treatment partner–
assisted 
ART  
 
Patient-
administered 
standard of care  
ART  
 
Gross et al.  
[44] 
Randomized 
controlled trial 
38 37 Botswana, 
Brazil, 
Haiti, Peru, 
South 
Africa, 
Uganda, 
Zambia, 
Zimbabwe 
 
30 months;               
April 2009- 
September 
2011 
259  Partner-based      
modified directly 
observed therapy 
 
Standard of 
care 
 
 
Nakigozi et al 
[30] 
Randomized 
controlled trial 
37.6 37 Uganda 
 
15 months; 
October 2010 - 
January 2012 
1209 Patient-selected 
care buddy 
Standard of care 
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Kaihin et al [53] Cohort  18.2 19.4 Thailand 4 months; 
April–July 2011 
46 Experimental 
Group 
(Empowerment 
Intervention) 
 
Control 
Kunutsor et al 
[26] 
Randomized 
controlled trial 
39.1                         39.2 Uganda 8 months; 
March-  
September 2010 
174 Standard 
adherence 
intervention 
package plus 
treatment 
supporter 
intervention 
 
 
Standard intervention  
package 
  
Munoz et al [54] Cohort 31.7 31.9 Peru 17 months; 
December 2005 
- April 2007 
120 Community-based 
accompaniment 
with supervised 
antiretrovirals 
 
 
Control 
Coker et al [43]a Randomized 
controlled trial 
 
Not reported Not 
reported 
Nigeria 18 months; 
August 2006- 
January 2008 
 
400 Peer educators 
arm 
Standard of care 
Coker et al [43]b Randomized 
controlled trial 
Not reported Not 
reported 
Nigeria 18 months; 
August 2006- 
January 2008 
 
400 Home visits and 
peer educators 
arm 
Standard of care 
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Table 2 Risk of bias in included studies of cohort studies 
Study 
 
Selection 
(sample 
population) 
Selection 
(participation 
rate) 
Performance 
bias (outcome 
assessment) 
Performance 
bias (analytical 
methods to 
control for bias) 
 
Other form 
of bias 
Fatti et al. [45] High Low Unclear Low High 
Fatti et al. [46] High Low Unclear Low High 
Franke et al. [47] High Low Unclear Low High 
Grimsrud et al. [48] High Low Low Low High 
Grimwood et al. [49] High Low Unclear Low High 
Johnston et al [50] High Low Unclear Low High 
Kipp et al. [51] High Low Low Low High 
Luque-Fernandez et al. 
[27] 
High Low Unclear Low High 
Massavon et al. [52] 
Kaihin et al [53] 
Munoz et al. [54] 
High 
High 
High 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
High 
High 
High 
 
 
Table 3 Risk of bias in included studies of randomized controlled trials 
Study 
 
Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
outcome 
assessors 
(performance 
bias) 
Incomplete 
outcome data 
(attrition 
bias) 
 
Selective 
reporting 
(reporting 
bias) 
Other 
bias 
Chang et al. [21] Low Unclear Unclear Low Low Low 
Jaffar et al. [25] Low Low Unclear Low Low Low 
Kiweewa et al. [39] Low Low Unclear Low Low Low 
Mfinanga et al. [40] Low Low Unclear Low Low Low 
Nachega et al. [29] Low Low Unclear Low Low Low 
Selke et al. [41] Low Low Unclear Low Low Low 
Taiwo et al. [42] 
Gross et al. [44] 
Nakigozi at el. 
[30,44] 
Kunutsor et al. [26] 
Coker et al. [43] 
Low 
Low 
Low 
Low 
Low 
Unclear 
Low 
Low 
Low 
Low 
Unclear 
Low 
High 
Unclear 
Unclear 
Low 
Low 
Low 
Low 
High 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
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Figure legends 
Figure 1: PRISMA flow for study selection 
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Figure 2: Forest plot of optimal ART adherence comparing community-based 
ART versus facility-based ART 
 
 
 
 
Figure 3: Forest plot of virologic suppression comparing community-based ART 
versus facility-based ART 
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Figure 4: Forest plot of retention in care comparing community-based ART 
versus facility-based ART 
 
 
 
 
 
Figure 5: Forest plot of change in CD4 count comparing community-based ART 
versus facility-based ART 
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Figure 6: Forest plot of all-cause mortality comparing community-based ART 
versus facility-based ART 
 
 
 
 
 
Figure 7: Forest plot of loss to follow-up comparing community-based ART 
versus facility-based ART 
 
 
 
33 | P a g e  
 
 
 
